



PRESS RELEASE

CONTACT:

Darien Sutton

215-898-3988 | dsutton@wistar.org

FOR IMMEDIATE RELEASE: Wednesday, July 10, 2024

Revolutionizing Cancer Treatment: Wistar and Accelerated Biosciences Collaborate to Pioneer Transformative Immune Cell Therapies

PHILADELPHIA — (July 10, 2024) — The Wistar Institute ("Wistar") is pleased to announce a research collaboration with Accelerated Biosciences Corp. ("Accelerated Bio") aimed at creating a groundbreaking platform based on human trophoblast stem cells (hTSCs) to explore new immunotherapies that use Accelerated Bio's proprietary technology. This collaboration has the potential to transform the field of allogeneic immunotherapies by generating various types of immune cells from hTSCs.

Accelerated Bio's hTSC platform is the cornerstone of this collaboration. These hTSCs exhibit high plasticity and immune privilege, making them an ideal potential strategy for diverse medical and biotechnological applications -- including drug discovery, therapy development, biomanufacturing, and toxicology testing. The hTSCs are ethically sourced, pre-implantation, and early-stage pluripotent stem cells.

Luis J. Montaner, D.V.M., D. Phil., Vice President of Scientific Operations and Herbert Kean, M.D., Family Professor at The Wistar Institute, expressed his enthusiasm about the collaboration:

"Collaborating with Accelerated Bio aligns perfectly with Wistar's research objectives to develop new strategies for immunotherapy based on our understanding of the human immune system. We are excited to explore the innate capabilities of Accelerated Bio's hTSCs and harness their potential to engineer superior allogeneic cell therapies against various diseases such as HIV or cancer."

Yuta Lee, CEO of Accelerated Bio, emphasized the advanced capabilities of the hTSC platform: "Our



THE WISTAR INSTITUTE
3601 SPRUCE STREET, PHILADELPHIA, PA 19104
215-898-3700 | WISTAR.ORG



hTSC platform is not only the earliest ethically sourced pluripotent stem cell source available but also one of the most dynamic and versatile. This research collaboration with Wistar will enhance our understanding of hTSCs and demonstrate their potential to revolutionize the cell therapy industry."

Through this collaboration, Wistar and Accelerated Biosciences aim to develop a more efficient method for creating engineered allogeneic immune cells for immunotherapy by reducing manufacturing complexities, costs, and therapeutic risks.

###

About Accelerated Biosciences Corp.

Accelerated Bio is at the forefront of healthcare innovation, leveraging the groundbreaking potential of hTSCs to revolutionize precision medicine. Originating from an early and ethical source, hTSCs possess extraordinary abilities to perform the functions of various cell types with added genetic stability, natural immune privilege, and high expansion capacity. Accelerated Bio's extensive, robust, and unencumbered intellectual property portfolio ensures the freedom to innovate for both Accelerated Bio and its partners. For more information, please visit www.acceleratedbio.com

ABOUT THE WISTAR INSTITUTE

The Wistar Institute is the nation's first independent nonprofit institution devoted exclusively to foundational biomedical research and training. Since 1972, the Institute has held National Cancer Institute (NCI)-designated Cancer Center status. Through a culture and commitment to biomedical collaboration and innovation, Wistar science leads to breakthrough early-stage discoveries and life science sector start-ups. Wistar scientists are dedicated to solving some of the world's most challenging problems in the field of cancer and immunology, advancing human health through early-stage discovery and training the next generation of biomedical researchers. wistar.org.



A Cancer Center Designated by the
National Cancer Institute

THE WISTAR INSTITUTE
3601 SPRUCE STREET, PHILADELPHIA, PA 19104
215-898-3700 | WISTAR.ORG